Discover an innovative webinar exploring a novel single-cell method for breast cancer multiomics, linking genetic variations, copy number changes and gene expressions with focused panels. While the information obtained from whole genome sequencing (WGS) studies is a clear gold standard for discovery-based sequencing, current sequencing costs and informatics challenges frequently diminish WGS usage. Instead, applications focus on exonic spaces, particularly druggable targets. The majority of these are small, focused panels — resulting in a significant resolution gap between comprehensive WGS and these focal panels.
In this webinar, the featured speaker describes the utility of the IDT v2 exome hybrid capture after ResolveOME single-cell workflow in a cohort of cells derived from breast cancer patients. This enables single-cell resolution of single nucleotide variants (SNVs), copy number alterations and gene expression signatures with a small, targeted protein panel, allowing for a true multiomic assessment of this disease.
Briefly, prior to hybrid capture, the corresponding single-cell genomic libraries were subjected to low-coverage WGS (lcWGS) to ascertain copy number alterations, revealing ductal carcinoma in situ/ infiltrating ductal carcinoma of the breast (DCIS/IDC)-prototypical and heterogeneous chromosomal lesions. Full-transcript RNA-seq data and BioLegend antibody-based surface protein targets were jointly assessed from the transcriptomic libraries of ResolveOME, enabling cell type identification and phenotypic cell state inference. The data indicates the successful merging of the ResolveOME multiomic workflow with a single-cell exome survey, enabling analysis of copy number variants (CNV) in the context of a complete transcriptome with a focal targeted protein assessment.
Join this webinar to explore a new method detailing genetic insights into breast cancer, enabling precise assessment of variations, gene expressions and targeted proteins at a single-cell level.
Speaker
Katie Kennedy, PhD, ASCP (MB), Manager Services Department, BioSkryb Genomics
Katie Kennedy completed her undergraduate education and the University of Texas MD Anderson Cancer Center focusing on molecular genetics. Following this, she completed a PhD in Biomedical Sciences from the North Carolina State University College of Veterinary Medicine. During this time, she focused on translational medicine and was able to develop a diagnostic/prognostic assay in the veterinary space with the start-up company Sentinel Biomedical. After the acquisition, she moved toward having a higher impact on human medicine by taking a position in a CLIA lab and is currently at BioSkryb Genomics where she manages the services division.
Message PresenterWho Should Attend?
This webinar will appeal to Researchers and Clinicians in academia and industry who are interested in understanding breast cancer heterogeneity in individual cells.
What You Will Learn
Attendees will gain insights into:
- The heterogeneity seen in single-cell evaluations of early-stage tumors
- The linkage between tumor genomes and transcriptomes
Xtalks Partner
BioSkryb
BioSkryb Genomics is a rapidly growing organization that is transforming single cell molecular discovery and analysis. Through its single cell whole genome and whole transcriptome amplification tools, scientists and clinicians can gain an unprecedented view of the genome, transcriptome, and proteome within a single cell to better understand the drivers, mechanisms, and management of complex disease.
Related Webinars
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account